Clinical trials: Cardiovascular Disease Risk Reduction, active
Sudden Cardiac Death
Dilated Cardiomyopathy - Unknown Therapeutic Risk Reduction by Contempary Medication and Implantable Cardioverter-Defibrillators (DUTCH-ICD)
Research questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM) is under debate.
- Trial name
- DUTCH-ICD (NCT07415642)
- Testing
- ICD implantation
- Where
- 2 sites in Netherlands
- Volunteers
- 720 people
- Sponsor
- University Medical Center Groningen
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Alcohol Drinking, Drinking Behavior
Reducing Cardiovascular Risks: The Role of Alcohol Use
The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure.
- Conditions
- Alcohol Drinking, Drinking Behavior, At-risk Drinking, Cardiovascular Risk Factor
- Trial name
- NCT07783061
- Testing
- Alcohol Abstinence, Control arm
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- The University of Texas at Arlington
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Colchicine, ICH - Intracerebral Hemorrhage
Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage
Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies.
- Conditions
- Colchicine, ICH - Intracerebral Hemorrhage, Stroke, Dependence
- Trial name
- CoVasc-ICH2 (NCT06587737)
- Testing
- Colchicine 0.5 MG
- Volunteers
- 1,125 people
- Sponsor
- Population Health Research Institute
Stroke, Brain Ischemia
A Novel Rural Integrated Care and Early Prevention Model for Older Adults at High Risk of or Living With Stroke in China
This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults…
- Conditions
- Stroke, Brain Ischemia, Cerebral Hemorrhage, Transient Ischemic Attack
- Trial name
- NCT07628283
- Testing
- Enhanced Usual Stroke Care, Digital Health Platform-Supported Integrated Stroke Management
- Where
- 2 sites in China
- Volunteers
- 2,510 people
- Sponsor
- Jiangsu Province (Suqian) Hospital
Hypertension, Vascular Disease
Real-World Validation of A Minimally Disruptive Ambulatory Blood Pressure Monitoring (ABPM) Huawei Smartwatch in Malaysia
Background: Ambulatory Blood Pressure Monitoring (ABPM) is the gold standard for diagnosing high blood pressure (hypertension) because it tracks blood pressure continuously across day and night.
- Conditions
- Hypertension, Vascular Disease, Cardiovascular (CV) Risk, Cardiovascular Disease
- Trial name
- Huawei-SunU02 (NCT07913607)
- Where
- Malaysia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sunway University
Gestational Hypertension, Hypertension in Pregnancy
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum…
- Conditions
- Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia
- Trial name
- DAPA-HP (NCT06785116)
- Testing
- Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Michigan
Hypertension and Cardiovascular Risk Factors
Knowledge of Vascular Age Contributes to Improve the Collaboration Between Community Pharmacies and Primary Health Care Physicians in Reducing Blood Pressure in Hypertensive Patients.
Cardiovascular diseases are the main cause of death worldwide and elevated blood pressure (BP), called hypertension (HTN), is the principal and most frequent factor for suffering cardiovascular diseases.
- Trial name
- TOGETHER (NCT06761235)
- Testing
- Standard BP intervention, EVA intervention
- Where
- 6 sites in Austria, Portugal and 1 more
- Volunteers
- 1,246 people
- Sponsor
- Enrique Rodilla
Atherosclerotic Disease
CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction)
This clinical investigation is intended to confirm the application of a new intended purpose and a new indication for an already certified medical device.
- Trial name
- CAPTURE (NCT06910111)
- Testing
- Polyglucosamine
- Where
- 3 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Certmedica International GmbH
Alzheimer Disease (AD), Cardio Vascular Disease
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
The Arlington Longitudinal Optimal Healthy Aging (ALOHA) Study is a community-based research project led by the Marymount University Center for Optimal Aging (MCOA).
- Conditions
- Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome
- Trial name
- ALOHA (NCT07180147)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Marymount University
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Hypertension (HTN)
Actions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Blacks
To use practice facilitation (PF) + community health worker (CHW) facilitation as a practical and sustainable implementation strategy to support the implementation and evaluation of three multi-level evidence-based interventions…
- Trial name
- NCT05208450
- Testing
- Practice support And Community Engagement (PACE)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- NYU Langone Health
Cardiovascular Diseases (CVD), Cardiovascular Disease Prevention
Assessment and Prediction of Cardiovascular Health and Disease Risk Using Wearable Biometrics.
This prospective, observational cohort study will evaluate the associations between wearable-derived biometrics and cardiovascular health, quantified by the American Heart Association's Life's Essential 8 framework, as well as…
- Conditions
- Cardiovascular Diseases (CVD), Cardiovascular Disease Prevention, Cardiovascular Disease Risk Factor, Coronary Artery Disease (CAD)
- Trial name
- BEACON-HEART (NCT07401550)
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Acute Ischemic Stroke
An Application Provides Personalized Suggestions Based on Secondary Prevention Risk Factors to Stroke Patients
This study applied an application that provides personalized suggestions and explore the effect of this actual intervention on reducing the risk of stroke recurrence
- Trial name
- NCT07098143
- Testing
- Risk factor management
- Volunteers
- 5,092 people
- Sponsor
- Xuanwu Hospital, Beijing
Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk
LDL Cholesterol Reduction Following Ezetimibe Initiation
This clinical trial will study why some people have a larger drop in low-density lipoprotein cholesterol (LDL-C), known as "bad cholesterol," after starting ezetimibe.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol
- Trial name
- EZE-TRACK (NCT07839741)
- Testing
- Ezetimibe
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Universidade do Porto
Kidney Failure, Chronic, Hyperphosphatemia
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested.
- Trial name
- PHOSPHATE (NCT03573089)
- Testing
- Liberal phosphate target, Intensive phosphate target
- Where
- 126 sites in Australia, Brazil and 7 more
- Volunteers
- 3,600 people
- Sponsor
- The University of Queensland
Cardiovascular Risk, Obesity
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo.
- Trial name
- AMBIENCE (NCT07861100)
- Testing
- Zenagamtide
- Where
- 769 sites in United States, Argentina and 24 more
- Volunteers
- 8,500 people
- Sponsor
- Novo Nordisk A/S
Cardiovascular Disorder, Chronic Kidney Disease
Cancer and Blood Pressure Management, CARISMA Study
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are…
- Conditions
- Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma
- Trial name
- NCT04467021
- Testing
- Best Practice, Blood Pressure Measurement, Clinical Management
- Where
- 25 sites in United States
- Volunteers
- 61 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Diabetes Mellitus, Cardiovascular Diseases
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
This study used the diabetes prevention and follow-up research queue in Daqing and the public database of UKbiobank to evaluate the risk factors of cardiovascular and cerebrovascular events in diabetes patients, and built the…
- Conditions
- Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
- Trial name
- NCT06959784
- Testing
- semaglutide, Metformin
- Where
- China
- Volunteers
- 142 people
- Sponsor
- China-Japan Friendship Hospital